Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H13F2N |
| Molecular Weight | 197.2244 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC\C(CCC1=CC=C(F)C=C1)=C\F
InChI
InChIKey=VXLBSYHAEKDUSU-JXMROGBWSA-N
InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
| Molecular Formula | C11H13F2N |
| Molecular Weight | 197.2244 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Mofegiline (MDL 72,974A or (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, hydrochloride), is a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B) both in vitro and in vivo. In addition, mofegiline inhibits semicarbazide-sensitive amine oxidase activity from human serum and saphenous vein. In phase II studies, MDL 72,974A is proving to be a useful adjunct to conventional therapy of Parkinson's disease. It seems mofegiline development was discontinued.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3266532
Curator's Comment: Palfreyman et al., 1988 ( Merrell Dow Research Institute, Cincinnati, Ohio.)
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19053775 |
28.0 nM [Ki] | ||
Target ID: CHEMBL2993 |
3.6 nM [IC50] | ||
Target ID: CHEMBL3437 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11061216 |
10.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27202 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
48 mg single, oral dose: 48 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
14018 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
24 mg 1 times / day steady-state, oral dose: 24 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105170 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
48 mg single, oral dose: 48 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
54359 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
24 mg 1 times / day steady-state, oral dose: 24 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
48 mg single, oral dose: 48 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7554709 |
24 mg 1 times / day steady-state, oral dose: 24 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MOFEGILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
48 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
24 mg 1 times / day steady-state, oral Studied dose Dose: 24 mg, 1 times / day Route: oral Route: steady-state Dose: 24 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. | 2008-12-25 |
|
| Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. | 2004-09 |
|
| Design and early clinical evaluation of selective inhibitors of monoamine oxidase. | 1988 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8294896
In human volunteers, potent inhibition of platelet MAO-B activity was observed at submilligram doses (ED50 = 90 micrograms) following a single oral dose. Upon multiple oral doses of 100 micrograms, as much as 80% of MAO-B could be inhibited. In phase II studies, Mofegiline (MDL 72,974A) is proving to be a useful adjunct to conventional therapy. Patients (250) with Parkinson's disease, treated once daily with either 1 or 4 mg, together with L-Dopa and a decarboxylase inhibitor (MadoparR or SinemetR), saw significant improvements in symptoms compared with those on standard therapy without the inhibitor.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9013137
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:02:32 GMT 2025
by
admin
on
Wed Apr 02 07:02:32 GMT 2025
|
| Record UNII |
1FMJ6D8Y1B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C058000
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
C83968
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
DTXSID50869629
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
1FMJ6D8Y1B
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
Mofegiline
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
100000080353
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL489079
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
SUB09034MIG
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
6437850
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
119386-96-8
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
7058
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | |||
|
m831
Created by
admin on Wed Apr 02 07:02:32 GMT 2025 , Edited by admin on Wed Apr 02 07:02:32 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|